
The biopharmaceutical industry is undergoing a shift propelled by intricate biologics and their impact on global healthcare. With advancements in technology and subsequent therapies, particularly in antibody-based therapeutics, the industry’s landscape is witnessing a surge in innovative modalities, such as bispecific antibodies (BsAbs), reshaping treatment methodologies and market trajectories.

The biopharmaceutical industry is undergoing a shift propelled by intricate biologics and their impact on global healthcare. With advancements in technology and subsequent therapies, particularly in antibody-based therapeutics, the industry’s landscape is witnessing a surge in innovative modalities, such as bispecific antibodies (BsAbs), reshaping treatment methodologies and market trajectories.
Share article
Related Content